{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:41:53Z","timestamp":1790912513468,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,8,18]],"date-time":"2017-08-18T00:00:00Z","timestamp":1503014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,8,18]],"date-time":"2017-08-18T00:00:00Z","timestamp":1503014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1038\/leu.2017.264","type":"journal-article","created":{"date-parts":[[2017,8,18]],"date-time":"2017-08-18T10:08:48Z","timestamp":1503050928000},"page":"2844-2847","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib"],"prefix":"10.1038","volume":"31","author":[{"given":"W","family":"Qiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Antelope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M S","family":"Zabriskie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A D","family":"Pomicter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N A","family":"Vellore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Szankasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Rea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J M","family":"Cayuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T W","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M W","family":"Deininger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"O\u2019Hare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,18]]},"reference":[{"key":"BFleu2017264_CR1","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nature21702","volume":"543","author":"AA Wylie","year":"2017","unstructured":"Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature 2017; 543: 733\u2013737.","journal-title":"Nature"},{"key":"BFleu2017264_CR2","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/B978-0-12-397918-6.00007-0","volume":"548","author":"NS Gray","year":"2014","unstructured":"Gray NS, Fabbro D . Discovery of allosteric BCR-ABL inhibitors from phenotypic screen to clinical candidate. Methods Enzymol 2014; 548: 173\u2013188.","journal-title":"Methods Enzymol"},{"key":"BFleu2017264_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nchembio760","volume":"2","author":"FJ Adrian","year":"2006","unstructured":"Adrian FJ, Ding Q, Sim T, Velentza A, Sloan C, Liu Y et al. Allosteric inhibitors of Bcr-Abl-dependent cell proliferation. Nat Chem Biol 2006; 2: 95\u2013102.","journal-title":"Nat Chem Biol"},{"key":"BFleu2017264_CR4","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nature08675","volume":"463","author":"J Zhang","year":"2010","unstructured":"Zhang J, Adrian FJ, Jahnke W, Cowan-Jacob SW, Li AG, Iacob RE et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 2010; 463: 501\u2013506.","journal-title":"Nature"},{"key":"BFleu2017264_CR5","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00277-015-2539-0","volume":"95","author":"P Szankasi","year":"2016","unstructured":"Szankasi P, Schumacher JA, Kelley TW . Detection of BCR-ABL1 mutations that confer tyrosine kinase inhibitor resistance using massively parallel, next generation sequencing. Ann Hematol 2016; 95: 201\u2013210.","journal-title":"Ann Hematol"},{"key":"BFleu2017264_CR6","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1158\/0008-5472.CAN-12-3904","volume":"73","author":"T O'Hare","year":"2013","unstructured":"O'Hare T, Eide CA, Agarwal A, Adrian LT, Zabriskie MS, Mackenzie RJ et al. Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis. Cancer Res 2013; 73: 3356\u20133370.","journal-title":"Cancer Res"},{"key":"BFleu2017264_CR7","doi-asserted-by":"publisher","first-page":"518","DOI":"10.3389\/fphar.2016.00518","volume":"7","author":"H Miyata","year":"2016","unstructured":"Miyata H, Takada T, Toyoda Y, Matsuo H, Ichida K, Suzuki H . Identification of febuxostat as a NewStrong ABCG2 inhibitor: potential applications and risks in clinical situations. Front Pharmacol 2016; 7: 518.","journal-title":"Front Pharmacol"},{"key":"BFleu2017264_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13046-015-0275-x","volume":"34","author":"D Westover","year":"2015","unstructured":"Westover D, Li F . New trends for overcoming ABCG2\/BCRP-mediated resistance to cancer therapies. J Exp Clin Cancer Res 2015; 34: 159.","journal-title":"J Exp Clin Cancer Res"},{"key":"BFleu2017264_CR9","doi-asserted-by":"publisher","first-page":"5085","DOI":"10.1074\/jbc.M109.039206","volume":"285","author":"H Yuan","year":"2010","unstructured":"Yuan H, Wang Z, Gao C, Chen W, Huang Q, Yee JK et al. BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia. J Biol Chem 2010; 285: 5085\u20135096.","journal-title":"J Biol Chem"},{"key":"BFleu2017264_CR10","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1172\/JCI30890","volume":"117","author":"NP Shah","year":"2007","unstructured":"Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 2007; 117: 2562\u20132569.","journal-title":"J Clin Invest"},{"key":"BFleu2017264_CR11","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","volume":"26","author":"MS Zabriskie","year":"2014","unstructured":"Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell 2014; 26: 428\u2013442.","journal-title":"Cancer Cell"},{"key":"BFleu2017264_CR12","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1182\/blood.V126.23.138.138","volume":"126","author":"OG Ottman","year":"2015","unstructured":"Ottman OG, Alimena G, DeAngelo DJ, Goh Y-T, Heinrich MC, Hochhaus A et al. ABL001, a potent, allosteric inhibitor or BCR-ABL, exhibits safety and promising single-agent activity in a phase I study of patients with CML with failure of prior TKI therapy. Blood 2015; 126: 138.","journal-title":"Blood"},{"key":"BFleu2017264_CR13","doi-asserted-by":"publisher","first-page":"6934","DOI":"10.1021\/jm100555f","volume":"53","author":"X Deng","year":"2010","unstructured":"Deng X, Okram B, Ding Q, Zhang J, Choi Y, Adrian FJ et al. Expanding the diversity of allosteric BCR-ABL inhibitors. J Med Chem 2010; 53: 6934\u20136946.","journal-title":"J Med Chem"},{"key":"BFleu2017264_CR14","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1158\/1535-7163.MCT-12-0302","volume":"11","author":"R Sen","year":"2012","unstructured":"Sen R, Natarajan K, Bhullar J, Shukla S, Fang HB, Cai L et al. The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2. Mol Cancer Ther 2012; 11: 2033\u20132044.","journal-title":"Mol Cancer Ther"},{"key":"BFleu2017264_CR15","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1038\/leu.2015.35","volume":"29","author":"L Lu","year":"2015","unstructured":"Lu L, Saunders VA, Leclercq TM, Hughes TP, White DL . Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells. Leukemia 2015; 29: 1792\u20131794.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2017264.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2017264","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2017.264","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/leu2017264.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T17:35:58Z","timestamp":1648748158000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2017264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,18]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["BFleu2017264"],"URL":"https:\/\/doi.org\/10.1038\/leu.2017.264","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,18]]},"assertion":[{"value":"18 August 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TWK has financial interests to declare: Novartis speaker's bureau, Novartis advisory board. DR receives honoraria from BMS, Novartis, Incyte and Pfizer for non-promotional scientific lectures or advisory boards and is an investigator of Novartis-sponsored CABL001X2101 phase I trial. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}